share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰製藥 | 144:擬議出售證券
美股sec公告 ·  06/03 14:01
Moomoo AI 已提取核心訊息
Charles F. Wagner Jr., an officer at Vertex Pharmaceuticals Inc., is set to sell 3,250 shares of common stock on 06/03/2024, with an aggregate market value of approximately $1,495,000. The shares to be sold were acquired through restricted stock vesting as part of compensation on various dates in February 2023, with a total of 3,250 shares vested. Wagner's transaction follows a consistent pattern of selling vested shares, as reflected in the past three months' sales data, where the same number of shares were sold for gross proceeds of $1,478,067.50. The planned sale is in accordance with a pre-arranged trading plan adopted on 02/26/2024.
Charles F. Wagner Jr., an officer at Vertex Pharmaceuticals Inc., is set to sell 3,250 shares of common stock on 06/03/2024, with an aggregate market value of approximately $1,495,000. The shares to be sold were acquired through restricted stock vesting as part of compensation on various dates in February 2023, with a total of 3,250 shares vested. Wagner's transaction follows a consistent pattern of selling vested shares, as reflected in the past three months' sales data, where the same number of shares were sold for gross proceeds of $1,478,067.50. The planned sale is in accordance with a pre-arranged trading plan adopted on 02/26/2024.
vertex pharmaceuticals inc官員Charles F. Wagner Jr. 預計於2024年06月03日出售3,250股普通股,市值約為1,495,000美元。這些股份是作為2023年2月不同日期作為薪酬的限制性股票發放而獲得的,共計3,250股限制性股票。華格納的交易遵循過去三個月銷售數據反映的一致模式,銷售了同樣數量的股份,謀取了1,478,067.50美元的總收入。這項計劃出售是根據於2024年02月26日採納的預先安排的交易計劃進行的。
vertex pharmaceuticals inc官員Charles F. Wagner Jr. 預計於2024年06月03日出售3,250股普通股,市值約為1,495,000美元。這些股份是作為2023年2月不同日期作為薪酬的限制性股票發放而獲得的,共計3,250股限制性股票。華格納的交易遵循過去三個月銷售數據反映的一致模式,銷售了同樣數量的股份,謀取了1,478,067.50美元的總收入。這項計劃出售是根據於2024年02月26日採納的預先安排的交易計劃進行的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息